ReviewTropical diseases, travel medicine and vaccines2026
Traveling with HIV.
Review in Tropical diseases, travel medicine and vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
International travel is increasingly common, and it remains a clinical context in which preventable morbidity may occur if not adequately addressed through a comprehensive pre-travel consultation. This article provides a structured, evidence-informed framework for counseling people living with human immunodeficiency virus (HIV) who travel internationally, emphasizing the need for individualized assessment and proactive risk mitigation. We outline key domains relevant to travel health in people living with HIV, including legal and structural barriers, general health evaluation, vaccination planning, malaria prevention, sexual health, and strategies for managing expected and unexpected events during travel. Persistent HIV-related entry, stay, and residence restrictions in some countries may influence itinerary planning, disclosure, and access to healthcare abroad. From a clinical perspective, the cornerstone of safe travel is sustained viral suppression on antiretroviral therapy, with careful planning to ensure uninterrupted medication supply, adherence across time zones, and preparedness for loss or theft of medications. Drug-drug interactions are an important consideration, particularly when prescribing malaria chemoprophylaxis or antibiotics. Vaccination strategies should include routine and travel-specific immunizations, with attention to immune status, and the possibility of reduced immunogenicity requiring serological assessment or additional vaccine doses to obtain optimal response. Travel may increase sexual risk-taking and exposure to sexually transmitted infections (STIs), warranting targeted counseling on prevention, post-exposure strategies, and access to testing and treatment. Destination-specific precautions, such as malaria prevention, must combine rigorous mosquito avoidance measures with appropriate chemoprophylaxis compatible with antiretroviral therapy (ART) regimens. Overall, HIV-informed travel counseling should be considered a standard component of comprehensive HIV care, integrating medical, pharmacological, behavioral, and structural considerations to support safe travel and reduce avoidable complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.